Skip to main content
Premium Trial:

Request an Annual Quote

John Molloy, Mark Poznansky, Cheryl Reicin, Niclas Stiernholm

Premium

The Ontario Genomics Institute has named five new directors to its board: John Molloy, president and chief executive officer of Parteq Innovations; Mark Poznansky, president and scientific director of the Robarts Research Institute; Cheryl Reicin, practice leader of the technology and life sciences group at Torys; Niclas Stiernholm, chief executive officer of Trillium Therapeutics; and Brian Underdown, managing director of technology investing at MDS Capital.

Molloy holds an MBA from Queen's University, Poznansky received a PhD in physiology from McGill University, Reicin has a JD from Harvard Law School and a BA from Columbia University, Stiernholm holds a PhD in immunology from the University of Toronto, and Underdown has a PhD in immunology from Washington University in St. Louis.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.